Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and AbbVie. Yuvezzi’s commercialization will be supported by up to $235 million in financing.
The post Presbyopia Eye Drop From Startup Tenpoint Gets FDA Approval, Paving Way for $235M Financing appeared first on MedCity News.
